

  <b>Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch Process</b>	<b>Date of Issue:</b> May 19, 2022

**PAXLOVID™ (NIRMATRELVIR AND RITONAVIR)  
DISTRIBUTION, PRESCRIBING AND ASSESSMENT  
Pharmacy Process and Billing Instructions**

**BACKGROUND**

- On January 17, 2022, Health Canada authorized Paxlovid™ (nirmatrelvir and ritonavir), the first new oral antiviral treatment for COVID-19. Paxlovid™ is indicated for at-home treatment of adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe illness.
- Paxlovid™ is taken twice a day for five days. This treatment has been demonstrated to reduce hospitalization and death in patients diagnosed with COVID-19 when started within five days of symptom onset.
- A staged approach to Paxlovid™ deployment was required early in the program due to limited supply using a specialist prescriber pool and targeted pharmacies.
- Due to the current stable supply of Paxlovid™ and increased patient demand, access to Paxlovid™ is expanding to meet healthcare system needs.
- The PAXLOVID™ (NIRMATRELVIR AND RITONAVIR) DISTRIBUTION, PRESCRIBING AND ASSESSMENT program is in effective until October 31, 2022, or at the discretion of the Ministry of Health and/or the Chief Medical Health Officer.

**ELIGIBILITY**

Eligible prescribers:

- All pharmacists, physicians, and nurse practitioners are eligible to prescribe Paxlovid™ when the authorized process and [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) are used and all relevant professional regulations and legislation are followed.

Eligible patients:

- A patient must meet the following criteria to be eligible for publicly-funded Paxlovid™:
  - Saskatchewan resident with a valid Health Services Number; or
  - Non-resident or client without a valid Health Services Number;
and:
  - Qualifies for COVID-19 treatment with Paxlovid™ under the provincial criteria; and

- Receives a prescription on [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form.
- Paxlovid™ is publicly-funded and must be provided at no charge to eligible patients.

## **DEFINITIONS**

### **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-OTHER PRESCRIBER**

- Other Prescriber refers to all non-pharmacist prescribers of an initial course of Paxlovid™.

### **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER**

- Pharmacist Prescriber refers to all pharmacist prescribers of an initial course of Paxlovid™.

## **PAXLOVID™ DISTRIBUTION**

- Effective May 19, 2022, all community pharmacies are eligible to participate in the distribution of Paxlovid™.
- Pharmacies not already participating must express their interest in distributing Paxlovid™ by emailing [dpebimmunizations@health.gov.sk.ca](mailto:dpebimmunizations@health.gov.sk.ca).
- Publicly-funded Paxlovid™ will be distributed to eligible patients by participating community pharmacies when prescribed through the authorized process on the [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form.
- Pharmacies are eligible for payment when:
  - Paxlovid™ has been distributed to an eligible patient (**PAXLOVID™ DISTRIBUTION FEE**); or
  - Pharmacist assesses a prescription issued by another healthcare provider and determines that the patient is ineligible and/or requires escalation to the Saskatchewan Health Authority (SHA) Specialized Early COVID Therapeutics Team to receive either Paxlovid™ or other more suitable treatment (e.g., remdesivir) (**PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-OTHER PRESCRIBER** or **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER**).

### The pharmacist will:

- Ensure that the Paxlovid™ prescription is issued on the [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form developed by medSask.
  - Review [Mild COVID-19 Infection: Guidelines for Prescribing Paxlovid™](#) process and documents.
- When assessing a Paxlovid™ prescription:
  - Review the [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form for appropriateness and/or drug interactions.
  - Contact the prescriber to follow-up on treatment concerns that may require escalation or may result in the Paxlovid™ not being distributed to the patient.
  - If patient requires further escalation or a referral for remdesivir, provide the completed [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form to the SHA Specialized Early COVID Therapeutics Team.
- When distributing Paxlovid™ to an eligible patient:
  - Provide the Paxlovid™ prescription in a timely manner to meet the requirement to begin treatment within five (5) days of symptom onset.

- Adjust Paxlovid™ blister packs where required for renal dose adjustment by removing and disposing unnecessary nirmatrelvir tablets, as prescribed.
- Arrange contactless medication counselling and dispensing with the patient or caregiver.
- Support patient management of self-limiting adverse reactions and treatment concerns.

The pharmacy will:

- Submit the Paxlovid™ drug claim using the **PAXLOVID™ DISTRIBUTION FEE** to the Drug Plan and Extended Benefits Branch (DPEBB) as per Appendix I, when distributing Paxlovid™ to an eligible patient.
- Submit the **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-OTHER PRESCRIBER** or **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER** to the DPEBB as per Appendix II or Appendix IV, when eligible.
- Remain up-to-date with provincial Paxlovid™ distribution process and clinical drug updates.
- Monitor Paxlovid™ inventory to maintain a minimum of five (5) to ten (10) treatment courses on hand in the pharmacy and reorder to replenish pharmacy stock as directed.
  - See **APPENDIX V: PAXLOVID™ INVENTORY MANAGEMENT** for more information.
- Upon request, provide documentation related to provision of publicly-funded Paxlovid™ to the DPEBB.

The Drug Plan and Extended Benefits Branch (DPEBB) will:

- Pay pharmacies the **PAXLOVID™ DISTRIBUTION FEE** or **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-OTHER PRESCRIBER** or **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER** upon receipt of the electronic claim.
- Monitor provincial and pharmacy inventory of publicly-funded Paxlovid™ and adjust ordering parameters as required.
- Request and review documentation to confirm pharmacists and pharmacies have adhered to the Paxlovid™ distribution process.
- Recover related fees if the DPEBB determines, based on its review, there was inappropriate submission for this fee.
- Regularly review and update the Paxlovid™ distribution process as required.

**PHARMACIST PRESCRIBING FOR PAXLOVID™**

- Effective May 19, 2022, pharmacists have been granted temporary authority to prescribe Paxlovid™ to eligible patients using the approved process as determined by the Saskatchewan College of Pharmacy Professionals and the Ministry of Health.
- Treatment with Paxlovid™ requires a thorough assessment of the patient’s medical history to manage ongoing drug therapies and to provide follow-up assessment.
- Pharmacies are eligible for payment when:
  - A pharmacist issues a Paxlovid™ prescription [**MINOR AILMENT FEE – COVID-19 (PAXLOVID™)**]; or
  - The patient initially meets eligibility criteria but upon further review of the patient’s medical and/or drug history, the pharmacist determines that the patient is no longer eligible for Paxlovid™ or remdesivir treatment (**PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER**); or
  - The patient initially meets eligibility criteria but the pharmacist determines they are not eligible for “pharmacist prescribing,” but rather require further escalation to the SHA

Specialized Early COVID Therapeutics Team to receive either Paxlovid™ or other, more suitable treatment (e.g., remdesivir). Pharmacist must provide the completed [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form with referral (**PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER**).

The pharmacist will:

- Adhere to the *Regulatory Bylaws of the Saskatchewan College of Pharmacy Professionals*.
- Adhere to medSask's [Mild COVID-19 Infection: Guidelines for Prescribing Paxlovid™](#).
- Fully complete all sections of the [PRESCRIBER ASSESSMENT Mild COVID-19 \(Paxlovid™\)](#) form.
- Adhere to the DPEBB Minor Ailment Policy found on the secure website: <https://www.drugplan.health.gov.sk.ca>

The pharmacy will:

- Submit the Paxlovid™ drug claim using **PAXLOVID™ DISTRIBUTION FEE** to the DPEBB as per Appendix I.
- Submit the **MINOR AILMENT FEE – COVID-19 (PAXLOVID™)** to the DPEBB as per Appendix III.
- Submit the **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER** to the DPEBB as per Appendix IV when eligible.
- Submit relevant fees on the same day that the service was provided.
- Remain up-to-date with provincial Paxlovid™ distribution process and clinical drug updates.
- Upon request, provide documentation related to provision of publicly-funded Paxlovid™ to the DPEBB.

The Drug Plan and Extended Benefits Branch (DPEBB) will:

- Pay pharmacies the **MINOR AILMENT FEE – COVID-19 (PAXLOVID™)** or the **PAXLOVID™ INELIGIBILITY/REFERRAL ASSESSMENT FEE-PHARMACIST PRESCRIBER** upon receipt of an electronic claim.
- Request and review documentation to confirm pharmacists and pharmacies have adhered to the Paxlovid™ prescribing process.
- Recover related fees if the DPEBB determines, based on its review, there was inappropriate submission for this fee.
- Review and update the Paxlovid™ prescribing process as required.

The Saskatchewan College of Pharmacy Professionals will:

- Provide medSask's "[Mild COVID-19 Infection: Guidelines for Prescribing Paxlovid™](#)" to its members.
- Work with medSask to maintain and update the guidelines as appropriate.
- Communicate with members with respect to updates and timelines.

## **INCENTIVES**

**No incentives shall be provided** by the Proprietor, or an agent on behalf of the Proprietor, to any other person in relation to the provision of publicly-funded Paxlovid™. *"Incentives" means any money, gifts, donations to a charity, rebates, refunds, customer loyalty programs, points, coupons, discounts, goods and/or rewards which can be redeemed for a gift or other benefit.*

## **WHO TO CONTACT**

For questions related to **BILLING PROCEDURE** and **REGISTRATION OF A PHARMACY FOR PARTICIPATION IN THE PROGRAM**, contact the Drug Plan and Extended Benefits Branch (DPEBB) at 306-787-3317 (Regina) or 1-800-667-7581, or by email at [dpebimmunizations@health.gov.sk.ca](mailto:dpebimmunizations@health.gov.sk.ca).

For questions related to **POLICIES, STANDARDS AND GUIDELINES RELATED TO DISPENSING AND PRESCRIPTIVE AUTHORITY**, contact the Saskatchewan College of Pharmacy Professionals at 306-584-2292.

For questions related to **PROFESSIONAL PRACTICE**, contact the Pharmacy Association of Saskatchewan at 306-359-7277.

For questions related to **PAXLOVID™ CLINICAL SUPPORT** and **TO ACCESS EDUCATIONAL TOOLS AND WEBINARS**, contact medSask at 1-800-667-3425, email [druginfo@usask.ca](mailto:druginfo@usask.ca), or visit their website at <https://medsask.usask.ca/index.php>.

**Table 1: Billing Codes and Claim Limitations**

*\*These fees are unique to Paxlovid™ and are not eligible in conjunction with any other DPEBB professional service programs.*

Service	Details	pseudoDIN/DIN	Fee	Claim Limitations
<b>Minor Ailment Fee: Covid-19 (Paxlovid™) (MAF-P)</b>	When a pharmacist under the “Minor Ailment Program” issues a Paxlovid™ prescription.	00951375	\$18.00	One (1) claim per patient
<b>*Paxlovid™ Ineligibility/Referral Assessment Fee: Pharmacist Prescriber (IRAF-P)</b>	The patient initially meets eligibility criteria but upon further review of the patient’s medical and/or drug history, the pharmacist determines that the patient is no longer eligible for Paxlovid™ or remdesivir. <b>OR</b> The patient initially meets eligibility criteria but the pharmacist determines they are not eligible for “pharmacist prescribing” but rather require further escalation to the SHA Specialized Early COVID Therapeutics Team to receive either Paxlovid™ or other, more suitable treatment (e.g., remdesivir).	00951376	\$18.00	Four (4) claims every 365 days
<b>*Paxlovid™ Ineligibility/Referral Assessment Fee: Other Prescribers (IRAF-O)</b>	Pharmacist assesses a prescription issued by another healthcare provider and determines that the patient is ineligible and/or requires escalation to the SHA Specialized Early COVID Therapeutics Team to receive Paxlovid™ or other, more suitable treatment (e.g., remdesivir).	00951377	\$18.00	Four (4) claims every 365 days
<b>*Paxlovid™ Distribution Fee (PDF)</b>	When Paxlovid™ has been distributed to an eligible patient by the pharmacy.	02524031	\$20.00	One (1) claim per patient

## Appendix I: Paxlovid™ Distribution Fee Billing Procedure

1. Dispense Paxlovid™ and submit the drug claim using the Paxlovid™ DIN (02524031) with a \$20.00 fee in the acquisition cost (AC) field.
  2. The Paxlovid™ drug claim must be **submitted for adjudication** to DPEBB as a **single transaction**.
  3. Billing shall occur on a real-time basis and use the Billing Codes and Claim Limitations listed in Table 1.
  4. Ensure the Paxlovid™ prescription claim is recorded onto the patient's Pharmaceutical Information Program (PIP) profile, including reviewing and resolving failed transaction reports as soon as possible.
  5. If dispensing Paxlovid™ for a patient without a Saskatchewan Health Services Number, email the DPEBB to track utilization and arrange for an alternate fee billing process.
- The provincial supply of Paxlovid™ is publicly-funded and the medication must be provided to eligible patients at no charge.
  - The DPEBB pays 100% of the \$20.00 fee to the pharmacy.
  - Ensure the following fields are completed as follows:
    - **PATIENT IDENTIFIER** = nine-digit Health Services Number (HSN)
    - **DISPENSING DATE** = date of activity (e.g., May 19, 2022)
    - **RX NUMBER** = enter the sequential RX#
    - **HEALTH PROVIDER ORGANIZATION ID** = SK or SKCP (for Pharmacist Prescribing)
    - **HEALTH PROVIDER ID** = Physician/Nurse Practitioner (SPR ID #) or Pharmacist ID number (e.g., D1234)
    - **PHARMACIST ORGANIZATION ID** = SK
    - **PHARMACIST ID** = Pharmacist ID number (e.g., D1234)
    - **DIN** = 02524031
    - **COMPOUNDING FEE (CF)** = \$0.00
    - **COMPOUND NAME** = blank
    - **QUANTITY (QTY)** = 1
    - **DAYS SUPPLY** = 5
    - **ACQUISITION COST (AC)** = \$20.00
    - **DISPENSING FEE (DF)** = \$0.00
    - **MARKUP** = 00 / 00 / 00
    - **TOTAL RX COST** = \$20.00
    - **PATIENT PAID** = \$0.00
    - **ADJUDICATION FLAG** = Y

Please note:

- DPEBB will not accept paper claims.
- If you are unable to submit the record of the Paxlovid™ drug claim electronically through your Practice Management System, please use the secure DPEBB web page by logging on to <https://www.drugplan.health.gov.sk.ca>.
- If you are not sure how to install the WEB certificate, please contact your software vendor.

## Appendix II: Paxlovid™ Ineligibility/Referral Assessment Fee – Other Prescriber Billing Procedure

1. Pharmacist assesses a prescription issued by another healthcare provider and determines that the patient is ineligible and/or requires escalation to the SHA Specialized Early COVID Therapeutics Team to receive either Paxlovid™ or other, more suitable treatment (e.g., remdesivir).
2. Submit the claim using the ***Paxlovid™ Ineligibility/Referral Assessment Fee: Other Prescribers*** DIN (00951377) with an \$18.00 fee in the acquisition cost (AC) field.
3. The IRAF-O claim must be **submitted for adjudication** to DPEBB as a **single transaction**.
4. Billing shall occur on a real-time basis and use the Billing Codes and Claim Limitations listed in Table 1.
5. If prescribing Paxlovid™ to a patient without a Saskatchewan Health Services Number, email the DPEBB to track utilization and arrange for an alternate fee billing process.

- The DPEBB pays 100% of the \$18.00 fee to the pharmacy.
- Ensure the following fields are completed as follows:

▪ <b>PATIENT IDENTIFIER</b>	= nine-digit Health Services Number (HSN)
▪ <b>DISPENSING DATE</b>	= date of activity (e.g., May 19, 2022)
▪ <b>RX NUMBER</b>	= enter the sequential RX#
▪ <b>HEALTH PROVIDER ORGANIZATION ID</b>	= SKCP
▪ <b>HEALTH PROVIDER ID</b>	= Pharmacist ID number (e.g., D1234)
▪ <b>PHARMACIST ORGANIZATION ID</b>	= SK
▪ <b>PHARMACIST ID</b>	= Pharmacist ID number (e.g., D1234)
▪ <b>DIN</b>	= 00951377
▪ <b>COMPOUNDING FEE (CF)</b>	= \$0.00
▪ <b>COMPOUND NAME</b>	= blank
▪ <b>QUANTITY (QTY)</b>	= 1
▪ <b>DAYS SUPPLY</b>	= 1
▪ <b>ACQUISITION COST (AC)</b>	= \$18.00
▪ <b>DISPENSING FEE (DF)</b>	= \$0.00
▪ <b>MARKUP</b>	= 00 / 00 / 00
▪ <b>TOTAL RX COST</b>	= \$18.00
▪ <b>PATIENT PAID</b>	= \$0.00
▪ <b>ADJUDICATION FLAG</b>	= Y

Please note:

- DPEBB will not accept paper claims.
- If you are unable to submit the record of the Paxlovid™ drug claim electronically through your Practice Management System, please use the secure DPEBB web page by logging on to <https://www.drugplan.health.gov.sk.ca>.
- If you are not sure how to install the WEB certificate, please contact your software vendor.



**Appendix III: Minor Ailment Fee – COVID-19 (Paxlovid™) Billing Procedure**

1. After a **Paxlovid™ Distribution Fee** claim has been submitted, submit the **Minor Ailment Fee – Paxlovid™** claim, DIN (00951375) with an \$18.00 fee in the acquisition cost (AC) field.
2. The MAF-P claim must be **submitted for adjudication** to DPEBB as a **single transaction**.
3. Billing shall occur on a real-time basis and use the Billing Codes and Claim Limitations listed in Table 1.
4. If prescribing Paxlovid™ to a patient without a Saskatchewan Health Services Number, email the DPEBB to track utilization and arrange for an alternate fee billing process.

- The DPEBB pays 100% of the \$18.00 fee to the pharmacy.
- Ensure the following fields are completed as follows:

▪ <b>PATIENT IDENTIFIER</b>	= nine-digit Health Services Number (HSN)
▪ <b>DISPENSING DATE</b>	= date of activity (e.g., May 19, 2022)
▪ <b>RX NUMBER</b>	= enter the sequential RX#
▪ <b>HEALTH PROVIDER ORGANIZATION ID</b>	= SKCP
▪ <b>HEALTH PROVIDER ID</b>	= Pharmacist ID number (e.g., D1234)
▪ <b>PHARMACIST ORGANIZATION ID</b>	= SK
▪ <b>PHARMACIST ID</b>	= Pharmacist ID number (e.g., D1234)
▪ <b>DIN</b>	= 00951375
▪ <b>COMPOUNDING FEE (CF)</b>	= \$0.00
▪ <b>COMPOUND NAME</b>	= blank
▪ <b>QUANTITY (QTY)</b>	= 1
▪ <b>DAYS SUPPLY</b>	= 1
▪ <b>ACQUISITION COST (AC)</b>	= \$18.00
▪ <b>DISPENSING FEE (DF)</b>	= \$0.00
▪ <b>MARKUP</b>	= 00 / 00 / 00
▪ <b>TOTAL RX COST</b>	= \$18.00
▪ <b>PATIENT PAID</b>	= \$0.00
▪ <b>ADJUDICATION FLAG</b>	= Y

Please note:

- DPEBB will not accept paper claims.
- If you are unable to submit the record of the Paxlovid™ drug claim electronically through your Practice Management System, please use the secure DPEBB web page by logging on to <https://www.drugplan.health.gov.sk.ca>.
- If you are not sure how to install the WEB certificate, please contact your software vendor.

## Appendix IV: Paxlovid™ Ineligibility/Referral Assessment Fee – Pharmacist Prescriber Billing Procedure

1. The patient initially meets eligibility criteria but upon further review of the patient’s medical and/or drug history, the pharmacist determines that the patient is no longer eligible for Paxlovid™ or remdesivir treatment OR the pharmacist determines that the patient is not eligible for “pharmacist prescribing,” but rather requires further escalation to the SHA Specialized Early COVID Therapeutics Team to receive either Paxlovid™ or other, more suitable treatment (e.g., remdesivir).
2. Submit the claim using the ***Paxlovid™ Ineligibility/Referral Assessment Fee - Pharmacist Prescriber*** DIN (00951376) with an \$18.00 fee in the acquisition cost (AC) field.
3. The IRAF-P claim must be **submitted for adjudication** to DPEBB as a **single transaction**.
4. Billing shall occur on a real-time basis and use the Billing Codes and Claim Limitations listed in Table 1.
5. If prescribing Paxlovid™ to a patient without a Saskatchewan Health Services Number, email the DPEBB to track utilization and arrange for an alternate fee billing process.

- The DPEBB pays 100% of the \$18.00 fee to the pharmacy.
- Ensure the following fields are completed as follows:

▪ <b>PATIENT IDENTIFIER</b>	= nine-digit Health Services Number (HSN)
▪ <b>DISPENSING DATE</b>	= date of activity (e.g., May 19, 2022)
▪ <b>RX NUMBER</b>	= enter the sequential RX#
▪ <b>HEALTH PROVIDER ORGANIZATION ID</b>	= SKCP
▪ <b>HEALTH PROVIDER ID</b>	= Pharmacist ID number (e.g., D1234)
▪ <b>PHARMACIST ORGANIZATION ID</b>	= SK
▪ <b>PHARMACIST ID</b>	= Pharmacist ID number (e.g., D1234)
▪ <b>DIN</b>	= 00951376
▪ <b>COMPOUNDING FEE (CF)</b>	= \$0.00
▪ <b>COMPOUND NAME</b>	= blank
▪ <b>QUANTITY (QTY)</b>	= 1
▪ <b>DAYS SUPPLY</b>	= 1
▪ <b>ACQUISITION COST (AC)</b>	= \$18.00
▪ <b>DISPENSING FEE (DF)</b>	= \$0.00
▪ <b>MARKUP</b>	= 00 / 00 / 00
▪ <b>TOTAL RX COST</b>	= \$18.00
▪ <b>PATIENT PAID</b>	= \$0.00
▪ <b>ADJUDICATION FLAG</b>	= Y

Please note:

- DPEBB will not accept paper claims.
- If you are unable to submit the record of the Paxlovid™ drug claim electronically through your Practice Management System, please use the secure DPEBB web page by logging on to <https://www.drugplan.health.gov.sk.ca>.
- If you are not sure how to install the WEB certificate, please contact your software vendor.

## Appendix V: Paxlovid™ Inventory Management

- McKesson Canada is supporting distribution of publicly-funded Paxlovid™ to participating pharmacies.
- Access to Paxlovid™ is limited to registered pharmacies.
- Each carton of Paxlovid™ contains the entire five day treatment course: five daily pre-packaged blister cards with twice-daily dosing of two 150mg nirmatrelvir tablets and one 100mg ritonavir tablet.
- When dispensing, adjust Paxlovid™ blister packs where required for renal dose adjustment by removing and disposing unnecessary nirmatrelvir tablets, as prescribed.

### Pharmacy Inventory of Paxlovid™:

- To support timely access to drug therapy across the province and avoid delays, participating pharmacies are asked to monitor their inventory of Paxlovid™ to maintain a minimum supply.
- Pharmacies should maintain a minimum of five (5) to ten (10) treatment courses of Paxlovid™ inventory.
- When supply reaches fewer than five (5) courses, pharmacies may re-order up to ten (10) courses from McKesson.
  - Pharmacies should monitor Paxlovid™ demand in their communities.
- Prescription not picked up:
  - In some cases, pharmacies may fill a prescription for Paxlovid™ but the patient will not receive the drug (patient does not complete pick-up, treatment is no longer clinically appropriate due to progression of illness, etc.).
  - Pharmacies should reverse claims that are not picked up by patients within the five-day therapeutic treatment window **and** ensure that the prescription is removed from the patient's PIP profile.
  - Please contact DPEBB at [DPEBimmunizations@health.gov.sk.ca](mailto:DPEBimmunizations@health.gov.sk.ca) when this occurs to ensure appropriate tracking and billing occurs.
- Paxlovid™ treatment not completed:
  - In the event a patient does not complete their prescribed therapy with Paxlovid™, pharmacies should instruct patients to return unused tablets to the pharmacy to be disposed.
- Maintain Paxlovid™ inventory and dispensing records and report to the DPEBB as requested.
- Report Paxlovid™ supply issues or unexpected wastage to the DPEBB.

### Ordering from McKesson:

- Participating pharmacies will order Paxlovid™ (nirmatrelvir and ritonavir) from McKesson after the first supply is shipped to their location.
- Ordering limits will be implemented to prevent stockpiling.
- Paxlovid™ item ID: 169930

### Transferring Prescriptions:

- Participating pharmacies are able to transfer Paxlovid™ prescriptions to another participating pharmacy as per Saskatchewan College of Pharmacy Professionals regulatory bylaws.
- The \$20.00 fee claim may only be submitted by the dispensing pharmacy.

### Transferring Paxlovid™ Stock:

- DPEBB approval is required prior to arranging any transfer.